💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

Medanta reports strong Q2 with 46.1% profit jump, expansion efforts

EditorAmbhini Aishwarya
Published 2023-11-10, 06:06 a/m
© Reuters.

Medanta has delivered a robust performance in the second quarter of the fiscal year 2024, demonstrating significant growth across several key financial and operational metrics. The healthcare provider reported a total income of ₹8,647 million for the quarter, with earnings before interest, taxes, depreciation, and amortization (EBITDA) reaching ₹2,336 million. Notably, there was a year-over-year (YoY) surge in profit after tax by 46.1% to ₹1,252 million.

Operational efficiency also saw improvement with a 17.8% YoY increase in Average Occupied Bed Days and a 4.8% YoY rise in Average Revenue Per Occupied Bed (ARPOB) to ₹61,003. These gains reflect Medanta's ability to enhance patient care while effectively managing its resources.

The company's developing hospitals—Medanta Lucknow and Medanta Patna—made significant contributions to the overall revenue and EBITDA, accounting for 31% and 38%, respectively. This indicates the successful expansion and integration of these facilities into Medanta's network.

The hospital group's outpatient department (OPD) pharmacy business experienced a notable growth of 39% YoY, and revenue from international patients increased by 20%. These figures underscore Medanta's growing reach and reputation in both domestic and international markets.

For the first half of FY2024, Medanta posted a total income of ₹16,592 million with an EBITDA of ₹4,329 million. The company also undertook capital expenditures amounting to ₹1,276 million during this period, allocating Rs. 308 million towards the development of the Noida hospital.

Mature hospitals within Medanta's portfolio showed robust growth as well, with a 19.5% YoY increase in revenue, highlighting the strength of established operations. The profit after tax for H1 FY2024 stood at ₹2,272 million (USD1 = INR83.327).

In addition to financial growth, Group CEO and Director Pankaj Sahni announced strategic initiatives aimed at fostering medical expertise and community health improvement. The Medanta Clinical Excellence Program has been launched for MBBS graduates in collaboration with the Health Sector Skills Council. Furthermore, the "TB Free Uttar Pradesh" program is set to be rolled out as part of Medanta's commitment to public health in the region.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.